Evidence map›Paper›PMID 35431510›Full record

ReviewWorld journal of gastroenterology2022

Epidemiology of stomach cancer.

Milena Ilic, Irena Ilic

Open access · hybridAbstract readReview
In one paragraph

Review in World journal of gastroenterology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 285 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
285citing papers in PubMed, 13 pooled it
93.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

285 citing papers in PubMed, 13 syntheses or guidelines pooled it, 451 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Global Progression Rates of Precursor Lesions for Gastric Cancer: A Systematic Review and Meta-Analysis.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2025
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Importance of Inclusion of Representative Populations in Pivotal Clinical Trials: Zolbetuximab as an Example.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026
    Article
  15. Article
  16. Article
  17. Diagnostics (Basel, Switzerland) · 2026
    Article
  18. Characterization of acquired capecitabine resistance in MKN-45 gastric cancer cells reveals preserved apoptotic sensitivity.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026
    Article
  19. Article
  20. Review

225 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Milena IlicDepartment of Epidemiology, Faculty of Medical Sciences, University of Kragujevac, Kragujevac 34000, Serbia. drmilenailic@yahoo.com.
Irena IlicFaculty of Medicine, University of Belgrade, Belgrade 11000, Serbia.
University of Belgrade · RS

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite a decline in incidence and mortality during the last decades, stomach cancer is one of the main health challenges worldwide. According to the GLOBOCAN 2020 estimates, stomach cancer caused approximately 800000 deaths (accounting for 7.7% of all cancer deaths), and ranks as the fourth leading cause of cancer deaths in both genders combined. About 1.1 million new cases of stomach cancer were diagnosed in 2020 (accounting for 5.6% of all cancer cases). About 75% of all new cases and all deaths from stomach cancer are reported in Asia. Stomach cancer is one of the most lethal malignant tumors, with a five-year survival rate of around 20%. There are some well-established risk factors for stomach cancer:

Indexed as

Helicobacter InfectionsHelicobacter pyloriStomach NeoplasmsFemaleHumansIncidenceMaleRisk FactorsEpidemiologyIncidenceMortalityPredictive factorsPreventionStomach cancerSurvival

Identifiers

PMID35431510
PMCPMC8968487
OpenAlexW4226203208

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.